Now that the majority of people living with HIV take combination antiretroviral therapy (ART), the
spectrum of causes of pyrexia of unknown origin (PUO) has changed compared with the pre-ART era.
In these guidelines, we focus on causes and evaluation of PUO among people living with HIV with
CD4 counts <3...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B....
These guidelines provide guidance on the diagnosis of HIV infection, the care of people living
with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.
They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 201...
This revised guideline provides updated information for the care of women with chronic viral infections who require intrauterine fetal diagnostic testing. Women with chronic viral infections who are pregnant or planning a pregnancy. Non-invasive screening tests for diagnosis: maternal serum placental ana...
In the health sector response to the HIV epidemic, collection, analysis and use of data are
crucial at every level, from patient care and monitoring through programme management and
national programme monitoring to global monitoring. This strategic information answers the
questions: “How are patients d...
These consolidated guidelines on HIV testing services (HTS) bring together existing and
new guidance on HTS across different settings and populations.
The World Health Organization (WHO) first released consolidated guidelines on HTS in
2015, in response to requests from Member States, national programme ...
This publication provides guidance on the public health response to pretreatment HIV drug resistance (HIVDR) to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) among people without prior antiretroviral (ARV) drug exposure or people with prior ARV exposure who are initiating or reinitiating first...
These consolidated guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, care and treatme...
